Lycia Therapeutics Inc. (LYCA)
LYCA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | LYCA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0001806540 |
| SEC industry code | Biological Products, (No Diagnostic Substances) (SEC code, stale: periodic reports ended never filed) |
| Incorporated in | DE |
Financials
No annual revenue in SEC XBRL data for this filer.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No recent periodic report | None on EDGAR |
| Cash and burn | no XBRL financials | None on EDGAR |
| Shares outstanding | No cover-page share count in XBRL | None on EDGAR |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, San Francisco, California, United States | PCAOB Form AP 2026-10-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| SEC reporting | The company has never filed a periodic report with the SEC, so its SEC industry code was never reviewed against one. | None on EDGAR |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-10-23 |
| Latest current report | 8-K | 2026-10-26 |
Source: SEC EDGAR submissions feed, 40 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.3% |
| 1 month | Not enough price history |
| 3 months | Not enough price history |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -5.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMCR | Immunocore Holdings plc | $28.88 | -3.54% | $1.5B |
| MESO | Mesoblast Limited | $12.45 | -6.18% | $1.6B |
| VIR | Vir Biotechnology Inc. | $9.58 | -3.82% | $1.6B |
| NVAX | Novavax Inc. | $8.06 | -5.45% | $1.3B |
| TSHA | Taysha Gene Therapies Inc. | $4.06 | -0.98% | $1.3B |
| ALVO | Alvotech | $4.41 | +5.13% | $1.7B |
| WWB | Windward Bio Group AG Common Shares | $30.04 | +5.40% | $1.7B |
| RXRX | Recursion Pharmaceuticals Inc. | $2.90 | -8.79% | $1.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier